Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

2.490 -0.140 (-5.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nkarta, Inc. - Common Stock

< Previous 1 2 Next >
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Nkarta Announces Pricing of $240 Million Underwritten Offering
From Nkarta, Inc.
Via GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
From Nkarta, Inc.
Via GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
From FN Media Group LLC
Via GlobeNewswire
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
From Nkarta, Inc.
Via GlobeNewswire
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET 
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
From Nkarta, Inc.
Via GlobeNewswire
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET 
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via TheNewswire.com
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.